TOI vs. TDOC, AHCO, GRAL, OMDA, PNTG, FTRE, CDNA, FLGT, CSTL, and AGL
Should you be buying Oncology Institute stock or one of its competitors? The main competitors of Oncology Institute include Teladoc Health (TDOC), AdaptHealth (AHCO), GRAIL (GRAL), Omada Health (OMDA), The Pennant Group (PNTG), Fortrea (FTRE), CareDx (CDNA), Fulgent Genetics (FLGT), Castle Biosciences (CSTL), and Agilon Health (AGL). These companies are all part of the "healthcare" industry.
Oncology Institute vs. Its Competitors
Oncology Institute (NASDAQ:TOI) and Teladoc Health (NYSE:TDOC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends, profitability and media sentiment.
Oncology Institute has a beta of 0.08, meaning that its share price is 92% less volatile than the S&P 500. Comparatively, Teladoc Health has a beta of 1.76, meaning that its share price is 76% more volatile than the S&P 500.
In the previous week, Teladoc Health had 3 more articles in the media than Oncology Institute. MarketBeat recorded 6 mentions for Teladoc Health and 3 mentions for Oncology Institute. Teladoc Health's average media sentiment score of 1.70 beat Oncology Institute's score of 0.89 indicating that Teladoc Health is being referred to more favorably in the news media.
Teladoc Health has a net margin of -8.16% compared to Oncology Institute's net margin of -14.26%. Teladoc Health's return on equity of -10.13% beat Oncology Institute's return on equity.
Oncology Institute has higher earnings, but lower revenue than Teladoc Health. Teladoc Health is trading at a lower price-to-earnings ratio than Oncology Institute, indicating that it is currently the more affordable of the two stocks.
Oncology Institute currently has a consensus target price of $7.00, suggesting a potential upside of 102.31%. Teladoc Health has a consensus target price of $9.80, suggesting a potential upside of 26.48%. Given Oncology Institute's stronger consensus rating and higher probable upside, equities analysts plainly believe Oncology Institute is more favorable than Teladoc Health.
36.9% of Oncology Institute shares are held by institutional investors. Comparatively, 76.8% of Teladoc Health shares are held by institutional investors. 8.5% of Oncology Institute shares are held by company insiders. Comparatively, 0.6% of Teladoc Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Teladoc Health beats Oncology Institute on 9 of the 17 factors compared between the two stocks.
Get Oncology Institute News Delivered to You Automatically
Sign up to receive the latest news and ratings for TOI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TOI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oncology Institute Competitors List
Related Companies and Tools
This page (NASDAQ:TOI) was last updated on 8/27/2025 by MarketBeat.com Staff
MarketBeat All Access